Could a common arthritis drug help PSC patients?
NCT ID NCT03561584
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether sulfasalazine, a drug used for arthritis, can improve liver health and symptoms in people with primary sclerosing cholangitis (PSC) who also have inflammatory bowel disease. 32 adults across the US took either the drug or a placebo for a set time. Researchers measured changes in liver enzymes and tracked side effects to see if the drug is safe and helpful.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
Chestnut Hill, Massachusetts, 02467, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug outperform standard care for a rare liver disease in teens?
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers
- Could IBD medications during pregnancy shape a Child's development?
- Could a new molecule tame a rare liver disease? early safety trial begins
- Can AI learn to grade endoscopy quality from video?
- Blood test may tame the tightrope walk of transplant drugs